Related references
Note: Only part of the references are listed.Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
Hyoun-Ah Kim et al.
FRONTIERS IN MEDICINE (2021)
Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era
Ping-Hsuan Hsieh et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review
Karin Luttropp et al.
BMJ OPEN (2019)
Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
Lykke Midtboll Ornbjerg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry
Maria V. Hernandez et al.
RHEUMATOLOGY INTERNATIONAL (2019)
The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany
Kathrin Ziegelbauer et al.
RHEUMATOLOGY (2018)
Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the US Department of Defense Population
Seina Lee et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors
Johan Dalen et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
Axel Svedbom et al.
PATIENT PREFERENCE AND ADHERENCE (2017)
Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
Peter Bhoi et al.
BMJ OPEN (2017)
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
Benjamin Chastek et al.
ADVANCES IN THERAPY (2017)
Encouraging adherence to long-term medication
Tim Usherwood
AUSTRALIAN PRESCRIBER (2017)
Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
Johan Dalen et al.
RHEUMATOLOGY INTERNATIONAL (2016)
Cost and Effectiveness of Biologics for Rheumatoid Arthritis in a Commercially Insured Population
Jeffrey R. Curtis et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2015)
A Paradigm Shift in Rheumatoid Arthritis over the Past Decade
Yuko Kaneko et al.
INTERNAL MEDICINE (2014)
Socioeconomic Burden of Immune-Mediated Inflammatory Diseases - Focusing on Work Productivity and Disability
Philip Jacobs et al.
JOURNAL OF RHEUMATOLOGY (2011)
Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis
Pengxiang Li et al.
VALUE IN HEALTH (2010)
Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs
Bijan J. Borah et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Treatment choices, preferences and decision-making by patients with rheumatoid arthritis
Frances Chilton et al.
MUSCULOSKELETAL CARE (2008)
Patient preferences in choosing anti-TNF therapies-R1
E. L. Williams et al.
RHEUMATOLOGY (2006)
The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work
X Li et al.
MEDICAL CARE (2006)
Share Paper
